Compare Moderna, Inc. (MRNA) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Oracle Corporation — how do they compare? Moderna, Inc. trades at $213.8 (market cap $78.65B), while Oracle Corporation trades at $141.92 (market cap $411.34B). The key difference: Oracle Corporation is far larger — about 5.2× Moderna, Inc.'s market cap, and Oracle Corporation pays a 1.47% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Oracle Corporation for 72 Days on average.
| MRNA | ORCL | |
|---|---|---|
Market Cap | $78.65B | $411.34B |
Volume | 37,373,437 | 41,276,815 |
Sector | Health | Technology |
52-Week High | $203.46 | $313.00 |
52-Week Low | $22.36 | $114.99 |
Typical Hold Time | 59 Days | 72 Days |
Enterprise Value | $74.80B | $535.15B |
Dividend Yield | — | 1.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Oracle (ORCL) trades at $143.56, down 0.83% amid a bearish technical signal, though recent earnings consistently beat expectations with Q2 2026 EPS of $1.92 versus $1.74 expected. The company shows strong fundamentals with 2025 revenue of $57.40B and net income margin of 26.36%, while analyst consensus remains bullish with a $236.52 price target. News highlights AI cloud growth of 120% in Q1 2026 but also layoffs and market concerns over AI spending cycles.
The outlook is mixed: robust AI-driven revenue growth and high profitability support upside, but technical weakness and macroeconomic risks like Fed policy pose near-term headwinds. Investors face opportunity from AI demand against volatility from high debt and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
